Sept 10 (Reuters) - BridgeBio Pharma ( BBIO ) said on
Tuesday it will stop development of its experimental therapy for
a genetic disease that affects the adrenaline-producing gland.
The drugmaker said the results of its early-to-mid stage
study testing the therapy did not meet the threshold to warrant
additional capital investment.
(Reporting by Puyaan Singh; Editing by Shinjini Ganguli)